1-[6-(4-Fluoro-benzyl)-3,3-dimethyl-2,3-dihydro-pyrrolo[3,2-b]pyridin-1-yl]-2-[(2R,5R)-5-methyl-2-((R)-3-methyl-morpholin-4-ylmethyl)-piperazin-1-yl]-ethanone dihydrochloride → AT-Iap
반응식
Cl.Cl.[F:3][C:4]1[CH:39]=[CH:38][C:7]([CH2:8][C:9]2[CH:10]=[C:11]3[N:17]([C:18](=[O:35])[CH2:19][N:20]4[CH2:25][C@@H:24]([CH3:26])[NH:23][CH2:22][C@@H:21]4[CH2:27][N:28]4[CH2:33][CH2:32][O:31][CH2:30][C@H:29]4[CH3:34])[CH2:16][C:15]([CH3:37])([CH3:36])[C:12]3=[N:13][CH:14]=2)=[CH:6][CH:5]=1>O>[F:3][C:4]1[CH:39]=[CH:38][C:7]([CH2:8][C:9]2[CH:10]=[C:11]3[N:17]([C:18](=[O:35])[CH2:19][N:20]4[CH2:25][C@@H:24]([CH3:26])[NH:23][CH2:22][C@@H:21]4[CH2:27][N:28]4[CH2:33][CH2:32][O:31][CH2:30][C@H:29]4[CH3:34])[CH2:16][C:15]([CH3:37])([CH3:36])[C:12]3=[N:13][CH:14]=2)=[CH:6][CH:5]=1참가 물질
실험 절차
1-[6-(4-Fluoro-benzyl)-3,3-dimethyl-2,3-dihydro-pyrrolo[3,2-b]pyridin-1-yl]-2-[(2R,5R)-5-methyl-2-((R)-3-methyl-morpholin-4-ylmethyl)-piperazin-1-yl]-ethanone dihydrochloride (1.8 g) was dissolved in water (50 mL) and the resulting solution extracted with ethyl acetate (50 mL). The aqueous phase was basified (pH 8) with saturated aqueous NaHCO3 then was extracted with DCM (5×50 mL). The combined DCM extracts were dried (Na2SO4) and evaporated in vacuo to give the title compound (1.72 g) as a foam. 1H NMR (Me-d3-OD): 8.24 (1H, s), 8.07 (1H, d), 7.24 (2H, dd), 7.03 (2H, t), 4.19-4.06 (1H, m), 3.99 (3H, d), 3.90 (1H, d), 3.71 (1H, d), 3.65-3.48 (2H, m), 3.19-2.70 (8H, m), 2.60-2.40 (2H, m), 2.26 (1H, s), 2.09-1.93 (1H, m), 1.87 (1H, d), 1.41 (6H, d), 1.04 (3H, d), 0.97 (3H, d).
후처리
- extractionthe resulting solution extracted with ethyl acetate (50 mL)
- extractionthen was extracted with DCM (5×50 mL)
- dry with materialThe combined DCM extracts were dried (Na2SO4)
- customevaporated in vacuo
출처 및 근거
- ORD 기록
- ord-ac26ab26d0c442e7a458146e1686ff50
- 출처 데이터셋
- uspto-grants-2015_04
- 특허 번호
- US09018214B2
반응 노트
불러오는 중…